Navidea Biopharmaceuticals (NAVB)
(Delayed Data from OTC)
$0.00 USD
0.00 (0.00%)
Updated Sep 20, 2024 09:31 AM ET
NA Value
NA Growth NA Momentum NA VGMBrokerage Reports
Navidea Biopharmaceuticals, Inc. [NAVB]
Reports for Purchase
Showing records 1 - 20 ( 41 total )
Company: Navidea Biopharmaceuticals, Inc.
Industry: Medical - Instruments
Company: Navidea Biopharmaceuticals, Inc.
Industry: Medical - Instruments
Constructive Dialog with the FDA Continues; Reiterate Buy and $8 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: BERNARDINO V
Company: Navidea Biopharmaceuticals, Inc.
Industry: Medical - Instruments
Company: Navidea Biopharmaceuticals, Inc.
Industry: Medical - Instruments
The Lede From 1Q21 Is to Prepare a 2Q21 EOP2 Package for the FDA; Reiterate Buy and $8 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: BERNARDINO V
Company: Navidea Biopharmaceuticals, Inc.
Industry: Medical - Instruments
Phase 2b Study Enrollment and Imaging Completed Against COVID Headwinds; Reiterate Buy and $8 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: BERNARDINO V
Company: Navidea Biopharmaceuticals, Inc.
Industry: Medical - Instruments
Momentum Into 2021 Building as Phase 2b in RA Nears Its Conclusion; Reiterate Buy and $8 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: BERNARDINO V
Company: Navidea Biopharmaceuticals, Inc.
Industry: Medical - Instruments
Tilmanocept Phase 2b Results Accepted for Presentation at ACR; Reiterate Buy Rating and $8 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: BERNARDINO V
Company: Navidea Biopharmaceuticals, Inc.
Industry: Medical - Instruments
Tilmanocept Set to Be Unleashed With Jubilant; Reiterate Buy; Raising PT to $8
Provider: H.C. Wainwright & Co., Inc.
Analyst: BERNARDINO V
Company: Navidea Biopharmaceuticals, Inc.
Industry: Medical - Instruments
A New Tool in RA Imaging is Born; Reiterate Buy With Our PT Raised to $6
Provider: H.C. Wainwright & Co., Inc.
Analyst: BERNARDINO V
Company: Navidea Biopharmaceuticals, Inc.
Industry: Medical - Instruments
On Track to Deliver Important Value-Creating Milestones in the Next 2-6 Months; Reiterate Buy and $4 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: BERNARDINO V
Company: Navidea Biopharmaceuticals, Inc.
Industry: Medical - Instruments
No Appreciable Impact on Tilmanocept Clinical Development or Regulatory Timelines; Reit Buy and $4 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: BERNARDINO V
Company: Navidea Biopharmaceuticals, Inc.
Industry: Medical - Instruments
Phase 2b Getting Closer to the Finish Line; Reiterate Buy and $4 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: BERNARDINO V
Company: Navidea Biopharmaceuticals, Inc.
Industry: Medical - Instruments
Funds Raised Remove a Near-Term Financing Overhang; Reit Buy With New $4 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: BERNARDINO V
Company: Navidea Biopharmaceuticals, Inc.
Industry: Medical - Instruments
Manocept Presents a New Model Image; Initiating Coverage at Buy and a $3 Price Target
Provider: H.C. Wainwright & Co., Inc.
Analyst: BERNARDINO V
Company: Navidea Biopharmaceuticals, Inc.
Industry: Medical - Instruments
Receives a CRL, Maintaining Rating but Lowering Price Target
Provider: RODMAN & RENSHAW, CO.
Analyst: KING M
Company: Navidea Biopharmaceuticals, Inc.
Industry: Medical - Instruments
Receives a CRL, Maintaining Rating but Lowering Price Target
Provider: RODMAN & RENSHAW, CO.
Analyst: KING M
Company: Navidea Biopharmaceuticals, Inc.
Industry: Medical - Instruments
Company: Navidea Biopharmaceuticals, Inc.
Industry: Medical - Instruments
Company: Navidea Biopharmaceuticals, Inc.
Industry: Medical - Instruments
Pharmalucence Receives FDA Approval for Use of Sulfur Colloid in Melanoma
Provider: RODMAN & RENSHAW, CO.
Analyst: KING M
Company: Navidea Biopharmaceuticals, Inc.
Industry: Medical - Instruments
Pharmalucence Receives FDA Approval for Use of Sulfur Colloid in Melanoma
Provider: RODMAN & RENSHAW, CO.
Analyst: KING M